In concordance with these findings, FGF-Erk1/2 signaling in lapatinib-resistant cancer cells was shown to stabilize the EMT transcription factor Twist, thereby maintaining the EMT phenotype and mediating drug resistance. Here, TWIST1 is linked to cancer.